Are you taking tremelimumab + durvalumab (Imjudo + Imfinzi)?

[AndreaWilson_Founder]

The American Association for Cancer Research (AACR) is seeking an HCC patient who is currently taking or has taken the combination therapy: tremelimumab + durvalumab (Imjudo + Imfinzi).

AACR would like to conduct a video interview for their annual Cancer Progress Report.

As a token of their appreciation, participants receive Affiliate Membership to AACR as well as a free subscription to Cancer Today, a quarterly magazine geared towards providing information and support for patients and survivors of cancer and their loved ones.

If you or a loved one is interested in sharing your story, please get in touch with Josh Goldstein by email or phone: [e-mail] or text him at 215-694-6033.

Let him know that Blue Faery's Liver Cancer Community referred you!

Note: This is a volunteer opportunity. There is no honorarium.

#livercancer #combinationtherapy